NervGen Pharma Corp
XTSX:NGEN

Watchlist Manager
NervGen Pharma Corp Logo
NervGen Pharma Corp
XTSX:NGEN
Watchlist
Price: 6.85 CAD -4.06% Market Closed
Market Cap: CA$503.9m

Operating Margin

0%
Current
No historical data
Comparison unavailable

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
0%
=
CA$0
/
CA$0

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
0%
=
CA$0
/
CA$0

Peer Comparison

Country Company Market Cap Operating
Margin
CA
NervGen Pharma Corp
XTSX:NGEN
524.1m CAD
Loading...
US
Eli Lilly and Co
NYSE:LLY
1T USD
Loading...
UK
Dechra Pharmaceuticals PLC
F:1PK
5.1B EUR
Loading...
US
Johnson & Johnson
NYSE:JNJ
529.7B USD
Loading...
CH
Roche Holding AG
SIX:ROG
275.3B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
210.3B GBP
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.8T DKK
Loading...
CH
Novartis AG
SIX:NOVN
221.9B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
269.1B USD
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
145.8B USD
Loading...

Market Distribution

Not Available
No Country distribution data available for this multiple

NervGen Pharma Corp
Glance View

Market Cap
503.9m CAD
Industry
Pharmaceuticals

NervGen Pharma Corp., a regenerative medicine company, engages in the discovery, development, and commercialization of therapeutics for the treatment of nerve damage, including spinal cord injuries and peripheral nerve injuries. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2019-03-13. The firm is engaged in the discovery, development and commercialization of pharmaceutical products for the treatment of nervous system injury due to trauma or disease as a result of underlying inflammation and/or neurodegeneration. The firm is advancing its lead compound, NVG-291, which is for the treatment of multiple sclerosis (MS), spinal cord injury (SCI) and Alzheimer’s disease. The firm has two wholly owned subsidiaries are NervGen US Inc. and NervGen Australia Pty Ltd.

NGEN Intrinsic Value
0.81 CAD
Overvaluation 88%
Intrinsic Value
Price
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Back to Top